Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation
NCT ID: NCT06450353
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1200 participants
OBSERVATIONAL
2024-05-31
2029-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
NCT00281801
Unrelated Donor Stem Cell Transplantation
NCT01364363
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
NCT03558386
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
NCT00898612
Musculoskeletal Outcomes After Bone Marrow Transplant
NCT00558948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary Objectives
* To prospectively evaluate time to transplant for allograft candidates at MDACC.
* To evaluate treatment-related mortality for allograft candidates at MDACC.
* To assess overall survival for allograft candidates at MDACC.
* To prospectively evaluate receipt of preferred unrelated donor for allograft recipients at MDACC.
* To evaluate receipt of an optimal graft for allograft recipients at MDACC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prospective evaluation
Participants are expected to be in this research study for up to 2 years after the participants bone marrow transplantation. However, your active participation will only last 1 day, when you sign the consent form and complete a questionnaire about your demographic information and ancestry (family ethnicity). For the rest of the study, information about the participants medical history, choice of bone marrow donor, and health outcomes will be collected from your medical record.
Patient Ancestry Questionnaires
Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patient Ancestry Questionnaires
Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Candidate for allogeneic transplantation
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Warren Fingrut, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
MD Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-04790
Identifier Type: OTHER
Identifier Source: secondary_id
2024-0253
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.